MARKETS / NASDAQ / DXCM

NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Dexcom Inc. DXCM

17 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$4.7B

▲ 15.6% YoY

Net income

$836.3M

▲ 45.1% YoY

Free cash flow

$1.1B

▲ 70.8% YoY

In brief

What this company does

Dexcom is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for the management of diabetes and metabolic health by patients, caregivers and clinicians around the world. As of December 31, 2025, it had approximately 11,100 employees around the globe, including 11,000 full-time employees. It primarily manufactures its products at manufacturing facilities in Mesa, Arizona and Penang, Malaysia. Although the majority of its revenue has been generated in the United States, it has expanded its operations to include additional markets in North America, Africa, Asia Pacific, Europe, Latin America and the Middle East. It launched its Dexcom G7 Continuous Glucose Monitoring System, or G7, in 2023, and the Dexcom G7 15 Day Continuous Glucose Monitoring System, or G7 15 Day, in late 2025. In August 2024, it launched Stelo, its biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin.

Written from the business description in DEXCOM INC's annual report to the U.S. Securities and Exchange Commission, filed 12 February 2026. Every sentence was checked against that document before publication.

Growth

USD 4.7B

Revenue, FY2025 · full 17-year series below

Revenue $B Net income $B

FY2025 · Revenue 4.7 · Net income 0.8

Compound annual growth

Revenue

+17.0%

+19.3%

+27.8%

+35.6%

Net income

+34.8%

+8.8%

EPS, diluted

+36.6%

Returned to shareholders

−4.1%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +19.3% a year over five years — but profit grew slower: net income at +8.8%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

18 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 19.6% · Net 17.9%

ROE

FY2025 · ROE 34.5%

Gross margin60.1%

Operating margin19.6%

Net margin17.9%

Return on assets13.0%

EBITDAUSD 1.2B

Each USD of equity produced 34 cents of profit this year.

Cash & shareholders

USD 471.9M

returned in FY2025 · dividends + net buybacks

Free cash flow $B

FY2025 · FCF 1.1

Net buybacks $M Dividends $M

FY2025 · Dividends — · Net buybacks 471.9

Dividends paid—

Net buybacksUSD 471.9M

Share of profit56.4%

Consecutive raises—

USD 471.9M in buybacks — 56% of the year's profit went back to shareholders.

Total assetsUSD 6.3B

EquityUSD 2.7B

CashUSD 917.7M

Current ratio1.88×

Equity funds 43% of total assets.

The 17-year record

17 fiscal years

Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Revenue $B	4.7	4.0	3.6	2.9	2.4	1.9	1.5	1.0	0.7	0.6	0.4	0.3	0.2	0.1	0.1	0.0	0.0
Operating income $B	0.9	0.6	0.6	0.4	0.3	0.3	0.1	−0.2	−0.0	−0.1	−0.1	−0.0	−0.0	−0.1	−0.0	−0.0	−0.0
EBITDA $B	1.2	0.8	0.8	0.5	0.4	0.4	0.2	−0.2	−0.0	−0.0	−0.0	−0.0	−0.0	−0.0	−0.0	−0.0	−0.0
Income tax $B	0.3	0.1	0.2	0.0	0.0	−0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−0.0	0.0	0.0	·
Net income $B	0.8	0.6	0.5	0.3	0.2	0.5	0.1	−0.1	−0.1	−0.1	−0.1	−0.0	−0.0	−0.1	−0.0	−0.1	−0.1
Free cash flow $B	1.1	0.6	0.5	0.3	0.1	0.3	0.1	0.1	0.0	0.0	0.0	0.0	−0.0	−0.0	−0.0	−0.0	−0.0
EPS, diluted $	2.09	1.42	1.30	0.82	0.53	1.33	1.10	−1.44	−0.58	−0.78	−0.72	−0.30	−0.42	−0.79	−0.68	−0.97	−1.21
Dividend / sh $	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·
Payout %	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·
ROE %	34.5	27.6	25.8	16.3	12.1	45.2	13.1	−19.2	·	·	·	·	·	·	·	·	·
Shares out B	0.38	0.39	0.39	0.39	0.39	0.10	0.09	0.09	0.09	0.08	0.08	0.08	0.07	0.07	0.07	0.06	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 82 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 13 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivitySurgical & Medical Instruments & Apparatus

Listed onNASDAQ

Incorporated inDelaware

Fiscal year endsDecember 31

Data on record since2009